

Corrigendum:

Effects of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one on serum levels of antioxidant enzymes in hyperlipidemic rats

(Volume 55, Number 2, 2023: Page: 99-107 <https://doi.org/10.19106/JMedSci005502202301>)

<https://doi.org/10.19106/JMedSci005503202311>

In the original article, both of authors and institution were incorrect. The correct version is given below:

Prasetyastuti^{1*}, Noviyanty Indjar Gama², Rahmah Dara Ayunda³

¹Department of Biochemistry, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta; ²Faculty of Pharmacy, Universitas Mulawarman, Samarinda, ³Department of Biochemistry Faculty of Medicine Universitas Mataram Indonesia

Errors in Abstract:

Dose 10,30 and 90 mg/200g BW were higher than control group that was not intervened.

Correct version

Dose 10,30 and 90 mg/200gBW were higher than the hyperlipidemic group

Errors in Abstrak:

10,30 dan 90 mg/200g BW lebih tinggi dibanding kelompok kontrol yang tidak diintervensi

Correct version

10,30 dan 90 mg/200g BW lebih tinggi dibanding kelompok hiperlipidemia

Errors in Abstrak:

Tikus hiperglikemia dibuat dengan diinduksi makanan kaya kolesterol dan asam kolic. Enzim SOD, CAT dan GPx dianalisis menggunakan metode spektrofotometri.

Correct version

Tikus hiperglikemia dibuat dengan diinduksi makanan kaya kolesterol dan asam kolic. Perlakuan diberikan secara oral dengan disonde. Setelah 4 Minggu perlakuan darah diambil. Enzim SOD, CAT dan GPx dianalisis menggunakan metode spektrofotometri.

Ethical Clearance Number Errors on Materials and Methods

Universitas Gadjah Mada (No.KE/FK/08/8/EC/2017).

Correct version

Universitas Gadjah Mada (No.KE/FK/0818/EC/2017).

Errors in Results (Serum level of SOD)

The results showed that the cholesterol-induced rats (HL) had lower serum SOD levels than the normal group (N) (FIGURE 1). Serum SOD levels in hyperlipidemic rats that were intervened with 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one dose 10,30 and 90 mg/200g BW were higher than HL group that was not intervened.

Correct version

The results showed that the cholesterol-induced rats (HL) had lower serum SOD levels than the normal group (N) (FIGURE 1). Serum SOD levels in hyperlipidemic rats that were intervened with 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one dose 10,30 and 90 mg/200g BW were higher than the hyperlipidemic group.

Error in Figure 1




FIGURE 1. Serum SOD levels (%) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL+ 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro-Wilk; data were tested with Anova test, Notation *: p <0.05 vs P; #: p <0.05 vs HL.

There was incorrect in Figure 1. Treatment group HL: 23.15± 4.88; P: 63.59± 3.22; F10: 31.64± 3.53; F30: 54.41± 3.94; F90: 58.91±4.88 it should HL: 39.45±4.88; P: 72.14±3.22; F10: 49.25± 3.53; F30: 56.47±/3.94; F90: 67.91±/ 4.88

Figure 1 correction




FIGURE 1. Serum SOD levels (%) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL+ 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro-Wilk; data were tested with Anova test, Notation *: p <0.05 vs P; #: p <0.05 vs HL.

There was incorrect in Figure 2




FIGURE 2. Serum CAT levels (U/mL) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL+ 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro-Wilk; data were tested with Anova, $p < 0.05$. Notation *: $p < 0.05$ vs P; #: $p < 0.05$ vs HL.

There was incorrect in Figure 2. Treatment group P: 5.12+/- 1.8 It should P: 5.12+/-0.18

Error in Figure 2




FIGURE 2. Serum CAT levels (U/mL) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL+ 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro-Wilk; data were tested with Anova, $p < 0.05$. Notation *: $p < 0.05$ vs P; #: $p < 0.05$ vs HL.

There was incorrect in Figure 3




FIGURE 3. Serum levels of GPx (U/mL) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL + 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro Wilk; data were tested with Anova $p < 0.05$. Notation *: $p < 0.05$ vs P; #: $p < 0.05$ vs HL.

There was incorrect Treatment group N : 79.85+/- 1.45 It should Treatment group N : 74.47+/-1.45

Figure 3 correction




FIGURE 3. Serum levels of GPx (U/mL) in hyperlipidemic rats. N: normal, HL: hyperlipidemia, P: HL + simvastatin, F10, F30, F90: HL + 7-OH-2-(4-OH3-methoxyphenyl)-chroman-4-one 10, 30, 90 mg/200g BW, respectively. Normality test with Shapiro Wilk; data were tested with Anova $p < 0.05$. Notation *: $p < 0.05$ vs P; #: $p < 0.05$ vs HL.

The authors would like to apologize for any confusion caused.